Epclusa and Rash macular - a phase IV clinical study of FDA data

Summary:

Rash macular is reported as a side effect among people who take Epclusa (sofosbuvir; velpatasvir), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Cogentin, and have Hepatitis c.

The phase IV clinical study analyzes which people have Rash macular when taking Epclusa. It is created by eHealthMe based on reports of 12,085 people who have side effects when taking Epclusa from the FDA, and is updated regularly.

What is Epclusa?

Epclusa has active ingredients of sofosbuvir; velpatasvir. eHealthMe is studying from 12,120 Epclusa users. Check the latest studies of Epclusa.

What is Rash macular?

Rash macular (small, flat red spots) is found to be associated with 1,363 drugs and 1,513 conditions by eHealthMe. Check the latest studies of Rash macular.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

12,085 people reported to have side effects when taking Epclusa.
Among them, 13 people (0.11%) have Rash macular.

Among these 13 people:

How long have people been on Epclusa when they have Rash macular? *

What is the gender of people who have Rash macular when taking Epclusa? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Rash macular when taking Epclusa? *

What are other drugs people take besides Epclusa? *

What are other side effects people have besides Rash macular? *

Rashes (redness): 4 people, 30.77%
Headache (pain in head): 2 people, 15.38%
Rash Erythematous (redness of the skin): 2 people, 15.38%
Hypersensitivity: 2 people, 15.38%
Eye Pruritus (eye itching): 2 people, 15.38%
Angioedema (rapid swelling of the dermis): 2 people, 15.38%
Fatigue (feeling of tiredness): 2 people, 15.38%
Skin Disorder (skin disease): 2 people, 15.38%
Adverse Reaction: 1 person, 7.69%
Abdominal Pain Upper: 1 person, 7.69%

What are the existing conditions these people have? *

Hepatitis C: 4 people, 30.77%
Oral Infection: 2 people, 15.38%
Hepatitis Viral: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Epclusa and have Rash macular?

- Check whether Rash macular is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epclusa:

Epclusa (12,120 reports)

Rash macular treatments and more:

Rash macular (36,440 reports)

Browse all side effects of Epclusa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash macular:

Rash macular (1,363 drugs)

Browse all the conditions that are associated with Rash macular:

Rash macular (1,513 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sofosbuvir; velpatasvir (the active ingredients of Epclusa) and Epclusa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.